Adaptimmune to acquire Boston-area cell therapy company TCR² Therapeutics
March 06, 2023 at 11:58 AM EST
The union will extend the cash runway of Adaptimmune into 2026.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|